Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial (SARS-CoV-2)
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022) - Comments
pubmed: 35543372  doi: 10.1093/cid/ciac345  issn: 1058-4838  issn: 1537-6591 

Xuan Ying Poh, Chee Wah Tan, I. Russel Lee, Jean-Marc Chavatte, Siew-Wai Fong, Tessa Prince, Catherine Hartley, Aileen Ying-Yan Yeoh, Suma Rao, Po Ying Chia, Sean WX Ong, Tau Hong Lee, Sapna P. Sadarangani, Ray JH Lin, Clarissa Lim, Jefanie Teo, Daniel RX Lim, Wanni Chia, Julian A. Hiscox, Lisa F.P. Ng